Forns X - Search Results

1

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. Poordad F, et al. Among authors: forns x. N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/NEJMoa1402869. Epub 2014 Apr 11. N Engl J Med. 2014. PMID: 24725237 Free article. Clinical Trial.

2

Hepatitis G virus infection in chronic hepatitis C: frequency, features and response to interferon therapy.

Sáiz JC, Ampurdanés S, Olmedo E, López-Labrador FX, Forns X, Guilera M, Tassies D, Costa J, Sánchez-Tapias JM, Jiménez de Anta MT, Rodés J. Sáiz JC, et al. Among authors: forns x. J Hepatol. 1997 Apr;26(4):787-93. doi: 10.1016/s0168-8278(97)80243-7. J Hepatol. 1997. PMID: 9126790

3

Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma.

López-Labrador FX, Ampurdanés S, Forns X, Castells A, Sáiz JC, Costa J, Bruix J, Sánchez Tapias JM, Jiménez de Anta MT, Rodés J. López-Labrador FX, et al. Among authors: forns x. J Hepatol. 1997 Dec;27(6):959-65. doi: 10.1016/s0168-8278(97)80137-7. J Hepatol. 1997. PMID: 9453419

4

Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases.

Ramos-Casals M, García-Carrasco M, López-Medrano F, Trejo O, Forns X, López-Guillermo A, Muñoz C, Ingelmo M, Font J. Ramos-Casals M, et al. Among authors: forns x. Medicine (Baltimore). 2003 Mar;82(2):87-96. doi: 10.1097/00005792-200303000-00003. Medicine (Baltimore). 2003. PMID: 12640185 Free article. Review.

5

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL, Forns X, Erhardt A, Crönlein J, Chaves RL, Yong CL, Nehmiz G, Steinmann GG. Hinrichsen H, et al. Among authors: forns x. Gastroenterology. 2004 Nov;127(5):1347-55. doi: 10.1053/j.gastro.2004.08.002. Gastroenterology. 2004. PMID: 15521004 Clinical Trial.

6

Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C.

Puig-Basagoiti F, Forns X, Furčić I, Ampurdanés S, Giménez-Barcons M, Franco S, Sánchez-Tapias JM, Saiz JC. Puig-Basagoiti F, et al. Among authors: forns x. J Gen Virol. 2005 Apr;86(Pt 4):1067-1075. doi: 10.1099/vir.0.80526-0. J Gen Virol. 2005. PMID: 15784900

7

Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.

Herrmann E, Zeuzem S, Sarrazin C, Hinrichsen H, Benhamou Y, Manns MP, Reiser M, Reesink H, Calleja JL, Forns X, Steinmann GG, Nehmiz G. Herrmann E, et al. Among authors: forns x. Antivir Ther. 2006;11(3):371-6. Antivir Ther. 2006. PMID: 16759054 Clinical Trial.

8

Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection.

Feliu A, Carrión JA, Massaguer A, Martínez-Bauer E, García-Retortillo M, González P, Costa J, Sánchez-Tapias JM, Forns X. Feliu A, et al. Among authors: forns x. J Viral Hepat. 2006 Aug;13(8):544-51. doi: 10.1111/j.1365-2893.2006.00714.x. J Viral Hepat. 2006. PMID: 16901285

9

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.

Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu M, Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-1 Study Team. Zeuzem S, et al. Gastroenterology. 2010 Oct;139(4):1257-66. doi: 10.1053/j.gastro.2010.06.066. Epub 2010 Jun 27. Gastroenterology. 2010. PMID: 20600013 Clinical Trial.

10

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK; SPRINT-1 investigators. Kwo PY, et al. Lancet. 2010 Aug 28;376(9742):705-16. doi: 10.1016/S0140-6736(10)60934-8. Epub 2010 Aug 6. Lancet. 2010. PMID: 20692693 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

350 results

Search Page